New hope for brain cancer: experimental combo enters human trials

NCT ID NCT06102525

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 25 times

Summary

This early-stage trial tests a new drug called RZ-001 combined with valganciclovir in people with glioblastoma, an aggressive brain cancer. The study aims to find the safest dose and see if the treatment can shrink tumors or help people live longer. About 43 adults whose tumors have a specific marker (hTERT) will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, 05505, South Korea

    Contact

  • Gachon University Gil Medical Center

    RECRUITING

    Incheon, 21565, South Korea

    Contact

  • Samsung Medical Center

    RECRUITING

    Seoul, 06351, South Korea

    Contact

  • Seoul National University Bundang Hospital

    RECRUITING

    Seongnam-si, 13620, South Korea

    Contact

  • Severance Hospital, Yonsei University Health System

    RECRUITING

    Seoul, 03722, South Korea

    Contact

  • The Catholic University of Korea, Incheon St. Mary's Hospital

    RECRUITING

    Incheon, 21431, South Korea

    Contact

Conditions

Explore the condition pages connected to this study.